The text reads T1D RELAY a study for those newly diagnsoed with type 1 diabetes. Segments of light blue, dark blue and red lines run diagonally in the background.
Research Spotlight
Read more
Newly diagnosed with type 1 diabetes? Help us find out if a novel combination therapy can preserve insulin production
TrialNet’s latest clinical study will test two established immune therapies—rituximab-pvvr followed by abatacept—to see if the combination can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).
JAKPOT T1D is a study for those newly diagnosed with T1D. The background of the image is blue with bursts of color in the lower left side.
Research Spotlight
Read more
New onset study now open for enrollment — TrialNet launches study to test JAK inhibitors in type 1 diabetes
TrialNet researchers are testing two promising new treatments to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).
Raised hands appear from the bottom of the image with the text "HELP US STOP-T1D". The background of the image is pale green and contains Y-shaped autoantibodies arranged into the shape of a stop sign.
Research Spotlight
Read more
New prevention study now open for enrollment – Help us find out if a low dose immunotherapy can STOP-T1D
TrialNet researchers are testing low-dose anti-thymocyte globulin (ATG), an immunotherapy, to find out if it can delay or prevent type 1 diabetes (T1D) in people at high risk of clinical diagnosis (Stage 3) within two years.
